Leukemia trials

AI-generated summary

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy is being studied. Conditions: Lymphoma, Leukemia • Eligibility: * INCLUSION CRITERIA: * Participants with disease * Participants are diagnosed with relapsed/refractory leukemias or lymphomas, and are scheduled to receive CAR T-cell treatment in one of the…. Goal: Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants is being studied. Conditions: Graft-versus-leukemia, Graft vs Host Disease, Graft Rejection • Eligibility: * INCLUSION CRITERIA-TRANSPLANT RECIPIENTS: Patients surviving three years or more from date of first stem cell transplant who have been treated. -With an experimental allogeneic stem cell transplant…. Goal: This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center. Patients are monitored for their response to treatment, disease relapse, and later-occurring effects of the transplant. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Heart, Lung, and Blood Institute (NHLBI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) is being studied. Conditions: Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia +2 • Eligibility: Inclusion Criteria: * Patients with relapsed/refractory CLL who meet iwCLL criteria for requiring treatment. * Patients with measurable disease as defined by at least one of: circulating lymphocytosis…. Goal: This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). The names of the study drugs involved in this study are: * Roginolisib (a novel type of PI3-kinase delta inhibitor) * Venetoclax (a type of B-cell lymphoma 2 inhibitor) * Rituximab (a type of monoclonal antibody) Phase/Status/Sponsor: Unknown phase; RECRUITING; Jennifer R. Brown, MD, PhD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a first-in-human Phase 1 study of STX-0712 to test its safety and early signs of activity in adults with advanced CMML or relapsed/refractory monocytic AML who have no other approved treatment options. The trial is open-label and non-randomized, with two parts: dose escalation to find safe dose levels, then dose expansion to further assess safety and preliminary efficacy. Participants receive a single intravenous infusion of STX-0712 every 21 days and stay on treatment until stopping criteria are met, with safety, PK, PD, and early efficacy data collected. Key exclusions include acute promyelocytic leukemia or extramedullary AML, active infections, recent stem cell transplant or major immunosuppressive therapy, significant cardiovascular disease or QT prolongation, and active HIV or HBV/HCV or other cancers requiring therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma is being studied. Conditions: T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell +5 • Eligibility: Inclusion Criteria: 1. Adult patients with T-cell lymphoma \[PTCL (all subtypes), T-PLL, ATLL, and CTCL (all subtypes)\] in partial or complete remission between day +35 and +120 from…. Goal: This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jonathan Brammer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study is being studied. Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma • Eligibility: Inclusion Criteria: * Participants must have a confirmed diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (collectively referred to as CLL throughout) according to the…. Goal: This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families is being studied. Conditions: Leukemia, Non Hodgkin Lymphoma • Eligibility: Inclusion Criteria: * 0 to 22 years of age * Diagnosis of leukemia or non-Hodgkin lymphoma * Spanish as preferred language for patient, parent or guardian * Received…. Goal: This study will seek to improve communication with Spanish speaking families and patients with Cancer and Blood Disorders. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Colorado, Denver.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial is testing whether pacritinib works better or is safer than hydroxyurea for adults with advanced proliferative chronic myelomonocytic leukemia (CMML). - About 66 adults with this condition will be randomly assigned to pacritinib twice daily or hydroxyurea for up to 48 weeks. - The study aims to learn if pacritinib provides better disease control and tolerability, with follow-up for about a year after treatment ends. - Key exclusions include recent other cancers (within 2 years, with some exceptions), prior JAK inhibitor use, recent stem cell transplant or immunosuppressive therapy, and significant heart, liver, or infection problems.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL is being studied. Conditions: T-cell Acute Lymphoblastic Leukemia • Eligibility: Inclusion Criteria: * Patient must have documented T cell ALL and must be in first or later hematologic CR or CRi after a minimum of 2 blocks of…. Goal: In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Eastern Cooperative Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials is being studied. Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS +9 • Eligibility: Inclusion Criteria: Patient must be ≥ 18 years and ≤ 39 years of age at registration. Patient must have a histologically confirmed diagnosis of primary cancer of any…. Goal: The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO. Phase/Status/Sponsor: Unknown phase; RECRUITING; Eastern Cooperative Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests adding Intensity Modulated Total Marrow Irradiation (IM-TMI), a targeted form of radiation, to the standard conditioning before a haploidentical stem cell transplant. It is for adults aged 18-75 with a related haploidentical donor (at least 5/10 HLA match) and certain high-risk blood cancers, such as relapsed or refractory AML or ALL, or poor-risk AML/ALL in remission, or poor-risk MDS. The goal is to see if IM-TMI increases cancer cell kill in the bone marrow and reduces relapse after transplant. Exclusion highlights include significant organ problems, inability to consent, or prior radiation to more than 20% of bone marrow–containing areas.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia is being studied. Conditions: ALL, Childhood, Pediatric Cancer, Toxicity, Drug +5 • Eligibility: Inclusion Criteria: * Age \> 1 year old and ≤18 years old at enrolment * Previously untreated * ALL diagnosis confirmed by morphology and flow-cytometry * Indian origins…. Goal: A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL). Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Geneva, Switzerland.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Children's Laughter and Fun Yoga as Adjunctive Pain Relief Following Chemotherapy. is being studied. Conditions: Acute Lymphoblastic Leukemia ALL • Eligibility: Inclusion Criteria: * Children aged 2-10 years. * Medically diagnosed with acute lymphoblastic leukemia (ALL) and currently receiving chemotherapy that includes dexamethasone pulses during the maintenance phase. *…. Goal: The goal of this clinical trial is to learn if a home-based program that combines laughter and fun yoga can help lower pain in children receiving chemotherapy. The study focuses on children with acute lymphoblastic leukemia who experience pain during treatment with chemotherapy and steroids. Phase/Status/Sponsor: Unknown phase; RECRUITING; Bahaa Bou Dargham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia is being studied. Conditions: Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia • Eligibility: Inclusion Criteria: 1. Patients with newly diagnosed B- precursor ALL or B-cell MPAL (single lineage) according to the WHO classification of tumours of haematopoietic and lymphoid tissues (revised…. Goal: This study is a treatment protocol with blinatumomab for infants under 1 year old who are diagnosed with acute lymphoblastic leukemia with a specific unfavorable genetic alteration. The purpose of the study is to improve the outcome of this disease in infants. Phase/Status/Sponsor: Unknown phase; RECRUITING; Princess Maxima Center for Pediatric Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether giving preemptive CIML natural killer (NK) cells expanded with IL-2 after a stem cell transplant can prevent relapse in adults with AML, MDS, or MDS/MPN overlap who are at high risk after transplant. It is for adults undergoing a reduced-intensity conditioning allogeneic stem cell transplant from a related donor, and plans to enroll up to about 30 participants. The trial aims to learn about the safety and potential effectiveness of CIML NK cell therapy plus IL-2 over a follow-up period of up to 3 years, with various monitoring tests along the way. Key exclusions include active infection or uncontrolled illness, pregnancy or inability to use contraception, HIV, active hepatitis B or C, prior allogeneic transplant within 7 days of infusion, and certain donor antibody or steroid-use restrictions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia is being studied. Conditions: Acute Lymphoblastic Leukemia, Acute Leukemias, Acute Myeloid Leukemia • Eligibility: Inclusion criteria: * Body weight greater than or equal to (\>=) 40 kilograms (kg) * Relapsed or refractory (R/R) acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A), nucleophosmin 1…. Goal: The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow). Phase/Status/Sponsor: Unknown phase; RECRUITING; Janssen Research & Development, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a multicenter screening study to find out how often the KIT D816V mutation occurs in people with suspected clonal mast cell disease. It has three cohorts: Cohort 1 includes people with suspected systemic mast cell activation disease; Cohort 2 includes people with hypermobility-related conditions, POTS, or early osteoporosis/osteopenia; Cohort 3 includes people with certain myeloid disorders per WHO criteria. The study aims to learn the prevalence of the KIT D816V mutation in these groups to inform diagnosis and future research. Exclusions include prior diagnosis of KIT-mutated monoclonal mast cell activation syndrome, cutaneous mastocytosis only, any systemic mastocytosis subtype, or mast cell sarcoma; Cohort 2 also excludes osteoporosis/osteopenia due to other known causes.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This randomized, controlled trial tests whether Romiplostim N01 can help platelets recover after haploidentical HSCT in adults with malignant blood diseases. About 130 patients will be assigned 1:1 to receive Romiplostim N01 (subcutaneous, weekly, starting at 5 µg/kg and up to 10 µg/kg, for up to 4 weeks or until platelets reach ≥100 × 10^9/L) or no rh-TPO/TPO-RA. The main goal is to see if Romiplostim increases the cumulative platelet engraftment by day +21, with additional measures of time to engraftment, transfusion needs, and safety. Key exclusions include uncontrolled infection or active malignancy, severe cardiovascular disease or thromboembolic risk, recent use of rh-TPO or TPO-RA, anticoagulation for thrombosis, and inability to consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia is being studied. Conditions: Leukemia, Myeloid Leukemia, Monocytic Leukemia • Eligibility: Inclusion Criteria: 1. Subject must have confirmation of non-APL AML by WHO criteria and have been treated with first-line venetoclax/HMA (azacitidine or decitabine). 2. Subject must have relapsed…. Goal: This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA. A preliminary dose-finding cohort will be followed by 3 expansion cohorts. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Colorado, Denver.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia is being studied. Conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL • Eligibility: Inclusion Criteria Eligibility Criteria for Donors: Apheresis and Manufacturing * Age ≥ 18 years old * At least single haplotype matched (≥ 3/6) family member * HIV negative…. Goal: This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative T-cells) for the treatment of patients ≤ 21 years old with relapsed and/ or refractory CD19-positive leukemia. Primary Objective To determine the maximum tolerated dose (MTD) and characterize the safety profile and dose-limiting toxicities (DLTs) of treatment with allogeneic CD19-CAR.CD45RA-negative T-cells in pediatric, adolescent and young adult patients ≤ 21 years of age, with relapsed and/or refractory CD19-positive leukemia. Phase/Status/Sponsor: Unknown phase; RECRUITING; St. Jude Children's Research Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia is being studied. Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia +9 • Eligibility: Inclusion Criteria: * Patients must have AML, ALL, high-risk MDS, or MPAL (also known as biphenotypic) meeting one of the following descriptions: * AML, ALL, or MPAL in…. Goal: This phase I/II trial studies the side effects and best dose of 211\^astatine(At)-BC8-B10 before donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed-phenotype acute leukemia. Radioactive substances, such as astatine-211, linked to monoclonal antibodies, such as BC8, can bind to cancer cells and give off radiation which may help kill cancer cells and have less of an effect on healthy cells before donor stem cell transplant. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fred Hutchinson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia is being studied. Conditions: Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia • Eligibility: Inclusion Criteria: * Documented informed consent of the participant * Agreement to allow the use of archival tissue from diagnostic tumor biopsies. * If unavailable, exceptions may be…. Goal: This phase Ib trial tests the safety, side effects, and effectiveness of humanized (hu)CD19-chimeric antigen receptor (CAR) T cell therapy in treating patients with CD19 positive B-cell acute lymphoblastic leukemia (ALL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). CAR T-cell therapy is a treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma is being studied. Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma • Eligibility: Inclusion Criteria: * Men and women \>= 18 years of age * Diagnosis of CLL/SLL meeting criteria as defined by International Workshop on Chronic Lymphocytic Leukemia (iWCLL) 2018…. Goal: This phase II trial tests how well acalabrutinib works in treating patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and evaluates how treatment with acalabrutinib affects heart function. Acalabrutinib is in a class of medications called kinase inhibitors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seema Bhat.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests MT-401-OTS, a cellular therapy, in adults with relapsed AML or high/very-high-risk MDS to evaluate safety and potential efficacy at escalating doses. It enrolls two groups of participants aged 65 and older: those with intermediate/high-risk AML with MRD or low blasts after prior therapy, and those with high/very-high-risk MDS with residual disease after HMA therapy. It is a Phase 1, open-label, multicenter dose-escalation study (3+3 design) to find a safe dose and gather early efficacy data, with an optional Cohort 4 for alternative dosing. Key exclusions include active CNS leukemia, active infections (e.g., HIV or hepatitis B/C), prior stem cell transplant, other active cancers (with limited exceptions), significant cardiac disease, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome is being studied. Conditions: Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission +9 • Eligibility: Inclusion Criteria: * Patients must have AML, ALL, high-risk MDS, or MPAL (also known as biphenotypic) meeting one of the following descriptions: * AML, ALL, or MPAL in…. Goal: This phase I/II trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10) followed by donor stem cell transplant in treating patients with high-risk acute leukemia or myelodysplastic syndrome that has come back (recurrent) or isn't responding to treatment (refractory). 211At-BC8-B10 is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fred Hutchinson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) is being studied. Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma • Eligibility: Inclusion Criteria: * CLL or SLL diagnosis * Patients must have been diagnosed with CLL (\> 5000 B-cells per uL of peripheral blood at any point during the…. Goal: People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. Phase/Status/Sponsor: Unknown phase; RECRUITING; VA Office of Research and Development.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether adults with myeloproliferative neoplasms can complete a 12-week Cardiac Lifestyle Program that includes tailored nutrition and physical activity. - It is a single-arm, feasibility pilot enrolling about 30 participants to learn if this lifestyle intervention is doable and safe for people with MPN. - Eligibility includes adults with MPN (ET, PV, prefibrotic MF, MF, or NOS) who have at least one cardiovascular risk factor; among MF patients, only those with low or intermediate-1 risk are eligible. - Exclusions include MF with intermediate-2 or high-risk disease, ECOG performance status >2, or any condition that would prevent safe exercise.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL is being studied. Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL) • Eligibility: Inclusion Criteria: * Participant must have CLL or SLL (WHO criteria). * Participant must require treatment according to iwCLL guidelines. * Participants must have no prior systemic therapy…. Goal: The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Phase/Status/Sponsor: Unknown phase; RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This phase II trial tests decitabine given together with one of three drugs—ruxolitinib, fedratinib, or pacritinib—before a donor stem cell transplant for people with accelerated or blast phase myeloproliferative neoplasms. The study aims to learn how well this pre-transplant therapy works to control disease and support transplant success. Eligible participants are adults with a history of MPN and at least 5% blasts in bone marrow or blood; key exclusions include pregnancy, active infection, and certain drug interactions or prior treatments that can’t be managed. Treatment cycles include intravenous decitabine plus one of the inhibitors, with blood and bone marrow samples collected, and follow-up for up to 5 years.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma is being studied. Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia • Eligibility: Inclusion Criteria: * Age 1-18.99 years * Diagnosis of acute leukemia / lymphoma as below: * Acute lymphoblastic leukemia (ALL) with at least 25% bone marrow blasts or…. Goal: The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; St. Jude Children's Research Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This platform trial tests post-transplant cyclophosphamide-based strategies to prevent graft-versus-host disease after a mismatched unrelated donor peripheral blood stem cell transplant in adults with hematologic cancers. - It compares a new drug combination to a standard one and aims to learn which works best and is safest for GVHD prevention. - Eligible participants are adults (18 and older) receiving MMUD PBSC transplant after myeloablative or reduced-intensity conditioning, with a partially matched donor (4/8–7/8) and adequate organ function and performance status. - Key exclusions include not having a suitable donor (no 8/8 match), prior allogeneic transplant, active infection, pregnancy, or enrollment in another GVHD prevention trial.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma is being studied. Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) • Eligibility: Inclusion Criteria: * Participant must have a diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) that meets 2008 Modified International Workshop for Chronic Lymphocytic…. Goal: This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status (Cohort 2). Phase/Status/Sponsor: Unknown phase; RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors is being studied. Conditions: Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia +6 • Eligibility: Inclusion Criteria: Histologically or cytologically confirmed diagnosis of the following malignancies: \- Phase 1: CP-CML, BP-CML, AP-CML ALL. AML. Other leukemias. Lymphoma. Any other tumors, including tumors of…. Goal: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias, lymphomas, and solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Incyte Biosciences International Sàrl.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies is being studied. Conditions: Central Nervous System Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia +3 • Eligibility: Inclusion Criteria: * Age 18 years or older * Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary…. Goal: This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma is being studied. Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma • Eligibility: Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Age between 18 and 39 with body mass index (BMI) ≥ 30 or age…. Goal: This phase II trial tests the safety, side effects, and effectiveness of asparaginase Erwinia chrysanthemi during induction chemotherapy followed by consolidation chemotherapy in treating high-risk adults with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma. Asparaginase Erwinia chrysanthemi, a type of protein synthesis inhibitor, is a drug that is made up of the enzyme asparaginase, which comes from the bacterium Erwinia chrysanthemi, and is used with other drugs in people who cannot take asparaginase that comes from the bacterium E. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP is being studied. Conditions: Childhood ALL • Eligibility: Inclusion Criteria: Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2 \- Exclusion Criteria: ALL L3 (Burkitt) ALL previously treated with chemotherapy…. Goal: The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation. Phase/Status/Sponsor: Unknown phase; RECRUITING; French Africa Pediatric Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood is being studied. Conditions: aGVHD, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia +1 • Eligibility: Inclusion Criteria: 1. Participants with the following hematologic malignancies: * Acute myelogenous leukemia (AML): High-risk AML including: * Antecedent hematological disease (e.g., myelodysplasia (MDS)) * Treatment-related * Complete…. Goal: The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease. Phase/Status/Sponsor: Unknown phase; RECRUITING; Case Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas is being studied. Conditions: Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia • Eligibility: Inclusion Criteria: the proportion of patients whose tumors have not progressed after treatment over a specific period of time. Specifically, DCR includes the percentage of patients who achieve…. Goal: Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently remain incurable. For indolent T/NK-cell lymphomas that are unresponsive to first-line treatment, there are few treatment options available and the prognosis is poor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institute of Hematology & Blood Diseases Hospital, China.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial is testing a treatment that uses oral arsenic together with ATRA (all-trans retinoic acid) for adults newly diagnosed with acute promyelocytic leukemia (APL). - It is non-randomized, multicenter, and prospective, sponsored by Instituto do Cancer do Estado de São Paulo; high-risk patients (WBC > 10×10^9/L) may receive low-dose chemotherapy. - The main goal is to measure 2-year overall survival and compare it to a historical IC-APL 2006 protocol, with several secondary outcomes like response, disease-free survival, relapse, and safety. - Eligible participants are adults aged 18–75 with confirmed APL; key exclusions include significant heart, liver, or kidney problems, other active cancers, HIV/HCV infection, pregnancy, and certain ECG abnormalities or other safety concerns.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is the Registry MDS, an observational study that follows patients with myelodysplastic syndromes (MDS) and therapy-related acute myeloid leukemia. It is currently recruiting and collects long-term data on diagnosis, medical history, laboratory results, and treatments from patients across 70 centers in France, with follow-up every six months. The goal is to learn how these diseases present and are managed over time and to understand care patterns and outcomes. Eligibility requires adults 18 or older with MDS or therapy-related AML who can give informed consent; those under 18 or unable to consent are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT) is being studied. Conditions: Acute Leukemia, Acute Lymphoblastic Lymphoma • Eligibility: Inclusion Criteria: 1. Age ≥ 0 years 2. Patients with a diagnosis of acute myeloid leukemia (AML), acute lymphoblastic leukemia or lymphoma (ALL), or acute leukemia of mixed…. Goal: This is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patients with acute leukemia undergoing first allogeneic blood or marrow Transplantation (BMT). The primary objective is to compare the rates of graft-versus-host disease-free and relapse-free survival (GRFS) between patients in the two cohorts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Early Detection and Screening of Hematological Malignancies - SANGUINE is being studied. Conditions: Hematologic Malignancy • Eligibility: Inclusion Criteria: General criteria for all study populations: 1. Male and female subjects ≥18 years of age 2. Ability to understand and willingness to sign a written informed…. Goal: This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions \[smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS)\], Hodgkin lymphoma (HL), diffuse large B cell lymphoma (DLBCL), Follicular lymphoma (FL), Marginal Zone lymphomas (MZL), acute myeloid leukemia (AML)\*, myelodysplastic syndrome (MDS), subjects at risk and control subjects with no malignant disease. \*Patients with a diagnosis of acute promyelocytic leukemia (APL) are not included Phase/Status/Sponsor: Unknown phase; RECRUITING; JaxBio Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests Monalizumab, an anti-NKG2A antibody, in adults with AML or MDS who are undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. - It is a Phase II, non-randomized, open-label, single-center study enrolling about 18 participants. - Participants receive 1 mg/kg Monalizumab IV on day +30 and day +44 after transplant to see if it improves graft-versus-host disease–free and progression-free survival at 1 year, and to assess safety and NK cell function. - Key exclusions include being under 18, active uncontrolled infections, CNS AML involvement, pregnancy, rapid relapse before day 30, acute GVHD before day +30, or having had a second allogeneic transplant.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies is being studied. Conditions: Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) +5 • Eligibility: GENERAL INCLUSION CRITERIA FOR ALL PATIENTS 1. Patients must be aged ≥18 years and ≤80 years with relapsed or refractory B-cell non-Hodgkin Lymphoma. 2. Absolute cluster of differentiation…. Goal: This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medical College of Wisconsin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies is being studied. Conditions: Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma +5 • Eligibility: Inclusion Criteria: * Adult patients at least 18 years of age, able to provide informed consent and willing to comply with all study procedures. * Participants with *…. Goal: CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed to determine the safety, tolerability, pharmacokinetics (affect of the body on the drug), pharmacodynamic (affect of the drug on the body), immunogenicity (development of antibodies against the drug), and preliminary anti-cancer effect of MGD024. Phase/Status/Sponsor: Unknown phase; RECRUITING; MacroGenics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial is being studied. Conditions: Acute Lymphoblastic Leukemia, Leukemia, Non-Hodgkin's Lymphoma • Eligibility: Inclusion Criteria: * Acute Lymphoblastic Leukemia (All Subtypes) if treated according to ALL protocols * Other Types of Leukemia (NK Cell Lymphoma/Leukemia, Biphenotypic Acute Leukemia) if treated according…. Goal: The GMALL registry serves the purpose of ALL research and quality assurance. The Registry collects data about diagnostics, treatment and outcome of Adult ALL Patients in the clinical routine, whether or not the patient is treated within a clinical trial. Phase/Status/Sponsor: Unknown phase; RECRUITING; Goethe University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers is being studied. Conditions: Chronic Lymphocytic Leukemia, Non-melanoma Skin Cancer (NMSC) • Eligibility: Inclusion Criteria: * Male or female subject aged ≥ 18 years. * Confirmed diagnosis of CLL or small lymphocytic leukemia (SLL) per iwCLL 2018 criteria. * History of…. Goal: This is a randomized, phase II, double-blind, placebo-controlled trial with planned crossover to the intervention arm after 1 year. Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Utah.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN is being studied. Conditions: AML (Acute Myeloid Leukemia), BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm) • Eligibility: Inclusion Criteria: 1. Patients of any gender, aged between 18 and 75 years (inclusive); 2. Positive expression of CD123 on tumor cells detected by flow cytometry; 3. Patients…. Goal: This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Chongqing Precision Biotech Co., Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Myeloproliferative Neoplasms (MPNs) Patient Registry is being studied. Conditions: Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia +7 • Eligibility: Inclusion Criteria: Diagnosis of one of the following myeloproliferative neoplasms (MPNs): * Atypical CML (aCML) * Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS), * Chronic myelomonocytic leukemia (CMML)…. Goal: The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Health Network, Toronto.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial is testing digital PCR to monitor measurable residual disease after allogeneic hematopoietic stem cell transplantation in people with leukemia, MDS, and related blood disorders, and it is currently recruiting. It aims to see if digital PCR can better detect MRD and predict relapse compared with standard methods like conventional qPCR or multicolor flow cytometry. Eligible participants must have had at least one fusion gene or tumor-associated mutation detected at diagnosis and must have neutrophil engraftment and have had at least one MRD test by digital PCR after transplant. Exclusions include patients who relapse or die before the first digital PCR test, and those with only DTA mutations (DNMT3A, TET2, ASXL1) or only germline mutations.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL is being studied. Conditions: Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult • Eligibility: Inclusion Criteria: 1. Male or female patients aged 18 years or older 2. Newly diagnosed Philadelphia chromosome positive(either t(9;22) and/or BCR-ABL positive and/ or FISH positive) acute lymphoblastic…. Goal: In recent years, immunotherapy (eg. blinatumomab, inotuzumab ozogamicin, CAR-T cells) has demonstrated a high safety and efficacy profile in relapsed/refractory (R/R）B-ALL. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institute of Hematology & Blood Diseases Hospital, China.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL is being studied. Conditions: Acute Lymphoblastic Leukemia, Adult • Eligibility: Inclusion Criteria: 1. Age: 18 to 60 years； 2. Diagnosis must comply with the Chinese Guidelines for Diagnosis and Treatment of Adult Acute Lymphoblastic Leukemia (2024 Edition), requiring…. Goal: This study aims to evaluate an integrated treatment protocol for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL), combining induction chemotherapy, consolidation therapy, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) to improve treatment efficacy and survival rates. The single-arm, open-label, multicenter study will enroll 50 newly diagnosed patients aged 18-60 years. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanxi Bethune Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil is being studied. Conditions: Acute Lymphoid Leukemia, Minimal Residual Disease, Gene Abnormality +1 • Eligibility: Inclusion Criteria: Patients between 16 and 50 years-old with newly diagnosed ALL, negative for Philadelphia chromosome not previously treated (except for hydroxyurea, corticosteroids, or intrathecal chemotherapy) with 20%…. Goal: In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic/follow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. Phase/Status/Sponsor: Unknown phase; RECRUITING; Instituto do Cancer do Estado de São Paulo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood is being studied. Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia • Eligibility: Inclusion Criteria: * The patient must have a diagnosis of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). * Stored diagnostic pre-treatment samples corresponding to the patient's…. Goal: A comprehensive mechanistic and epidemiological study to obtain banked cord blood samples from consecutive childhood leukemia patients enrolled in the COG Project:EveryChild (APEC14B1) study. Will attempt to backtrack the initiating genomic alteration identified in the matched diagnostic leukemia sample and molecularly characterize pre-leukemic cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; Children's Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) is being studied. Conditions: CLL • Eligibility: Inclusion Criteria: * Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment * Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2 * Measurable disease…. Goal: The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL) Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; BeOne Medicines.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is an observational, prospective, multi-center study in Belarus to evaluate acalabrutinib use in real-world treatment of CLL. It includes adults who have been newly prescribed acalabrutinib monotherapy within the previous four weeks, who are either treatment-naïve or relapsed/refractory, with treatment decisions made by clinicians. The study will follow participants for about two years to learn about real-world effectiveness, safety, and quality of life. Exclusion criteria include prior BTK inhibitor therapy, participation in another ongoing trial, and pregnancy or breastfeeding. Status: Not yet recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Precision Physical Exercise for Personalized Onco-Hematology. is being studied. Conditions: Hematologic Cancer, Colon Cancer, Breast Cancer +3 • Eligibility: Inclusión criteria: * Adult patients (≥18 years), capable of signing the informed consent and willing to participate in the study. * Performance status (ECOG) 0-2. * Specific inclusion…. Goal: Physical exercise, particularly strength training, has become an effective strategy to improve physical function, muscle mass, and quality of life in cancer patients. However, the biological mechanisms underlying these benefits remain poorly understood, especially during active treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University of Salamanca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests adding Decitabine and Venetoclax to a reduced-intensity conditioning transplant using fludarabine and melphalan before an allogeneic stem cell transplant for people with high-risk AML and MDS. It is for adults aged 18–75 who have a related or unrelated stem cell donor and are eligible for reduced-intensity conditioning before transplant. The study aims to assess safety, tolerability, and preliminary activity of this drug combination, using a standard 3+3 design and monitoring dose-limiting toxicities through day 28 after the transplant. Key exclusions include prior autologous transplant within 3 months, prior allogeneic transplant, active HIV, pregnancy or breastfeeding, uncontrolled infection, cirrhosis, and known hypersensitivity to Decitabine, Venetoclax, or ATG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests onvansertib, a PLK1 inhibitor, in adults with recurrent or treatment-refractory chronic myelomonocytic leukemia (CMML) or MDS/MPN overlap neoplasms. It uses a dose-escalation design to find the right dose and then expands at that dose, with the drug given by mouth daily and ongoing bone marrow tests and ultrasound imaging. The study will assess safety and adverse events and look for signs of activity such as complete remission, overall remission, spleen response, and symptom changes. Eligible participants are adults with CMML or MDS/MPN overlap disease; key exclusions include progression to acute leukemia, active CNS disease, QT prolongation risk, pregnancy, and prior exposure to a PLK1 inhibitor.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is an observational, multicenter study to find out how common familial AML/MDS is among people with AML or MDS who have a relative with a hematologic cancer or an early-onset cancer (under 40). It includes adults diagnosed between 2014 and 2022 and uses both retrospective and prospective data, with no intervention. Each year, participating sites will be surveyed to count new AML/MDS diagnoses to estimate incidence, and participants will be followed through December 2023 for at least one year. The study aims to identify and describe patients with familial MDS/AML or signs of known hereditary susceptibility to AML/MDS; there are no listed exclusion criteria.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Allo HSCT Using RIC and PTCy for Hematological Diseases is being studied. Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia +15 • Eligibility: Inclusion Criteria: * Age 0 to 75 years of age with Karnofsky score ≥ 70% (≥ 16 years) or Lansky score ≥ 50 (\< 16 years). * 5/6…. Goal: This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Masonic Cancer Center, University of Minnesota.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease is being studied. Conditions: Leukemia, Multiple Mieloma, Advanced Solid Tumors +3 • Eligibility: Inclusion Criteria: * ≥ 18 years age; diagnosed with refractory lymphomas, or leukemia or multiple myeloma or advanced solid tumors and estimated prognosis \> 3 months; * able…. Goal: This is a mixed-method, device-free and drug-free multicenter interventional study. The study aims at facilitating end-of-life conversations within the doctor-patient relationship through the use of the Go Wish Game (GWG) and supporting patients, their caregivers and healthcare professionals to complete Advance Care Panning documentation. Phase/Status/Sponsor: Unknown phase; RECRUITING; Azienda USL Reggio Emilia - IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a longitudinal cohort study to see if cancer treatment accelerates early aging in adolescents and young adults with cancer, by measuring aging markers before therapy and one year later. It includes patients aged 18-39 with a confirmed cancer diagnosis who are about to start systemic therapy with curative intent. The main goal is to see how the senescence marker P16 changes over one year, and it also looks at SASP, vascular markers, and cardiovascular risk factors related to treatment and patient/tumor characteristics. Measurements are taken at two visits and include blood tests and a physical exam (weight, height, waist-hip ratio, blood pressure); key exclusions are inability to understand consent, treatment with immune checkpoint inhibitors or anti-angiogenic therapy, and prior systemic therapy or radiotherapy for another cancer (with limited exceptions).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding hyperbaric oxygen therapy around an allogeneic peripheral blood stem cell transplant is safe and whether it can improve engraftment and reduce complications like graft-versus-host disease, mucositis, infections, and neutrophil recovery. - It is for adults undergoing allogeneic PBSC transplant for certain myeloid cancers and disorders; there are two cohorts, but only the second cohort is currently recruiting. - The second cohort includes people with CMML, aCML, chronic monocytic leukemia, chronic neutrophilic leukemia, myelofibrosis, and MDS/MPN overlap syndrome. - Eligibility requires adults aged 18-75 with adequate organ function and performance status; key exclusions include pregnancy, severe lung disease needing oxygen, active infection, ear/sinus problems, claustrophobia, seizures, and ongoing tobacco use around transplant.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome is being studied. Conditions: Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia +2 • Eligibility: Inclusion: 1. Patients will have a diagnosis of CLL or SLL or RTand are: a) Cohort 1: Patients with treatment naïve CLL/SLL who meet IWCLL criteria for treatment…. Goal: This phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab and obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This phase II trial tests whether adding venetoclax to ASTX727 (decitabine plus cedazuridine) improves outcomes for bone marrow cancer in CMML and MDS/MPN with excess blasts compared with ASTX727 alone. - It is for adults with MDS/MPN overlap syndrome with at least 5% marrow blasts who meet certain health criteria. - Participants are randomly assigned to either ASTX727 plus venetoclax or ASTX727 alone, and the study looks at complete remission rates and other response and survival measures. - Key exclusions include pregnancy, uncontrolled central nervous system disease, significant cardiac disease, recent extensive prior MDS/MPN therapy, and other safety-related conditions (e.g., grapefruit product restrictions).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests a combination of guadecitabine (a chemotherapy) and atezolizumab (an immunotherapy) in adults with advanced myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has relapsed or is refractory to prior treatment, and it includes newly diagnosed MDS as well. It is a two-part study (phase I dose-escalation followed by phase II) to find a safe dose and then evaluate how well the combination works. The trial aims to assess safety and tolerability and to measure efficacy, including overall survival, duration of response, and changes in transfusion dependence. Eligibility requires prior treatment with azacitidine or decitabine with progression or loss of response, plus certain health criteria; key exclusions include active autoimmune disease, active infection, prior PD-1/PD-L1 or CTLA-4 therapy, and pregnancy. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia is being studied. Conditions: Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia • Eligibility: Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Age between 12 and 55 * Eastern Cooperative Oncology Group (ECOG) ≤ 2 or…. Goal: This phase I/Ib trial tests the safety and side effects of asparaginase Erwinia chrysanthemi-recombinant-rywn (recombinant Erwinia asparaginase) and venetoclax in combination with blinatumomab and how well the combination works in treating patients with CD19 positive B-cell acute lymphoblastic leukemia (ALL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Asparaginase Erwinia chrysanthemi, a type of protein synthesis inhibitor, is a drug that is made up of the enzyme asparaginase, which comes from the bacterium Erwinia chrysanthemi. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia is being studied. Conditions: B Lymphoblastic Leukemia/Lymphoma • Eligibility: Inclusion Criteria: * Aged ≥3 and ≤70 years, gender and race unrestricted. * Bone marrow examination confirms the diagnosis of acute B-cell lymphoblastic leukemia (B-ALL) and meets one…. Goal: This study is designed to explore the safety and efficacy for patients with relapsed and/or refractory B-cell lymphoblastic leukemia. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anhui Provincial Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia is being studied. Conditions: Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia +1 • Eligibility: Inclusion Criteria: 1. The subject or guardian understands and voluntarily signs the Informed Consent Form (ICF); 2. Male or female, aged 12-65 years (including the cutoff value) when…. Goal: Traditional salvage chemotherapy has low efficacy and poor long-term prognosis for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Targeted CD19 CAR-T cell immunotherapy is an effective means of treating R/R B-ALL. Phase/Status/Sponsor: Unknown phase; RECRUITING; Peking University People's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests DFV890 as a single-agent treatment, using a dose-optimization part and a dose-expansion part in adults with myeloid diseases. - It targets very low, low, or intermediate risk MDS, very low/low/intermediate risk CMML, and high-risk CCUS. - The trial aims to learn about safety, tolerability, pharmacokinetics, pharmacodynamics, efficacy, and the best dose to use. - Key exclusions include recent systemic cancer therapy, hypersensitivity to DFV890, prior or concurrent use of drugs with the same mechanism, and certain drug interaction or metabolism issues (e.g., poor CYP2C9 metabolizers in expansion). - Participants will be treated for at least 24 weeks and must provide bone marrow samples at screening and at select timepoints.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CD34+ Transplants for Leukemia and Lymphoma is being studied. Conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute • Eligibility: Inclusion Criteria: * Malignant conditions or other life-threatening disorders correctable by transplant for which CD34+ selected, T-cell depleted allogeneic hematopoietic stem cell transplantation is indicated such as: 1.…. Goal: This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications for patients undergoing transplant for treatment of a blood malignancy (cancer) or blood disorder. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Guenther Koehne.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring is being studied. Conditions: Breast Cancer, Lung Cancer, Multiple Myeloma +2 • Eligibility: Inclusion Criteria: * All participants must be 18 years of age or older. * Subjects may be any stage and anywhere in the treatment continuum. * Subject participants…. Goal: The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Phase/Status/Sponsor: Unknown phase; RECRUITING; Carevive Systems, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests BTX-A51 capsules in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) to assess safety, how the drug acts in the body, and early signs of effectiveness. It is an open-label, dose-escalation study with three parts to find the maximum tolerated dose and the recommended phase 2 dose, and to explore a combination with azacitidine. Participants are adults (18+) who have exhausted standard treatments and have adequate organ function and performance status. Key exclusions include acute promyelocytic leukemia, very high white blood cell count, recent chemotherapy, recent stem cell transplant with active GVHD or systemic immunosuppression, active infections, significant heart disease, conditions affecting oral drug absorption, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests ziftomenib in patients with acute myeloid leukemia that has NPM1 mutations or KMT2A rearrangements who cannot receive standard therapy. The main goal is to see how many patients achieve complete remission (CR) or CR with hematologic improvement (CRh) after up to 6 treatment cycles. It also looks at how long responses last, overall survival, quality of life, and safety, with several additional efficacy measures such as overall response rate and MRD status. Key exclusions include active infections, a prolonged QT interval on ECG, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings is being studied. Conditions: CLL/SLL • Eligibility: Inclusion Criteria: * Age ≥ 18-year old * CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation * Patient requiring therapy for immune…. Goal: Chronic lymphocytic leukemia (CLL) is the most frequent form of leukemia in the Western World. The disease is characterized by the accumulation and proliferation of mature, monoclonal, CD5+ B-cells with specific immunophenotype in the peripheral blood (above 5x109/L), bone marrow and secondary lymphoid organs. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; French Innovative Leukemia Organisation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients is being studied. Conditions: Head and Neck Cancer, Urologic Cancer, Lung Cancer +2 • Eligibility: Inclusion Criteria: * 18 years of age or older * Histologic, cytologic or imaging confirmation of a malignancy in accordance with targeted indications * Written informed consent signed…. Goal: The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma. Innate Pharma is a biotechnology company which discovers and develops therapeutic antibodies that exploit the innate immune system to improve cancer treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Assistance Publique Hopitaux De Marseille.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study aims to understand why myeloproliferative neoplasms evolve into acute myeloid leukemia by doing detailed multi-omics analyses on about 120 post-MPN AML samples. - It will identify the dysregulated pathways and test a custom ex vivo drug panel to see effects on cell survival, differentiation, and stemness. - The three best drug candidates will be validated in patient-derived xenograft models and studied for their impact on clonal evolution using single-cell sequencing. - It is for people with a prior MPN (polycythemia vera, essential thrombocythemia, or primary myelofibrosis) who have AML with ≥20% blasts and usable bone marrow material with informed consent; key exclusion is not being affiliated with the French health insurance, and the study is not yet recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is an observational study testing whether lowering olverembatinib to 20 mg every other day can maintain response in adults with chronic myeloid leukemia in chronic or accelerated phase who have already achieved CCyR or BCR-ABL1 ≤1%. About 100 patients will be enrolled over 12–24 months and followed for at least 12 months to see if CCyR/BCR-ABL1 ≤1% is maintained, plus other responses and safety. Eligible participants are adults with CML in the chronic phase on 30 mg or 40 mg QOD who have had two consecutive confirmations of the target response and choose to switch to 20 mg QOD; key exclusions include pregnancy, uncontrolled infection or severe instability, inability to consent, or other safety concerns. The study is sponsored by Qian Jiang and will analyze time-to-event outcomes and adverse events to learn about safety and effectiveness of the dose change.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia is being studied. Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia • Eligibility: Inclusion Criteria: * Participants must have a new diagnosis of Philadelphia chromosome positive (Ph+) ALL by cytogenetics, FISH, or polymerase chain reaction (PCR). Diagnostic specimens must be submitted…. Goal: This phase II trial is to answer the question of "can adding the study drug, asciminib to usual treatment improve how chemotherapy works against Ph+ Acute Lymphoblastic Leukemia (ALL) and is this approach better than the usual approach for Ph+ALL?" Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; SWOG Cancer Research Network.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion is being studied. Conditions: Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes +8 • Eligibility: Inclusion Criteria: 1. Lack of suitable conventional donor (10/10 HLA matched related or unrelated donor) or presence of rapidly progressive disease not permitting time to identify an HLA-matched…. Goal: Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality. This is a phase I/II study that will test the safety and efficacy of hematopoietic cell transplantation (HCT) with ex-vivo T cell receptor Alpha/Beta+ and CD19 depletion to treat patients' underlying condition. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) is being studied. Conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia • Eligibility: Inclusion Criteria: * Age 18 years or older Age 18 years or older * ECOG performance status of 0 or 1 * Relapsed or refractory B cell ALL…. Goal: This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Autolus Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies is being studied. Conditions: Relapsed or Refractory B-cell Hematologic Malignancies, B-cell Acute Lymphoblastic Leukemia (B-ALL), Multiple Myeloma (MM) +3 • Eligibility: Inclusion Criteria 1. Voluntary participation with signed informed consent. 2. Pathologically confirmed CD19-positive and/or B-cell maturation antigen (BCMA)-positive hematologic malignancy according to the WHO 2017 classification, including but…. Goal: This single-arm, dose-escalation exploratory trial evaluates the safety and efficacy of Allogeneic CAR-T (UCAR-T) cell therapy in patients with relapsed or refractory CD19+/BCMA+ hematologic malignancies, including those with minimal residual disease (MRD). Eligible patients will receive lymphodepletion followed by a single infusion of UCAR-T cells, either post-transplant or without transplantation depending on disease status. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; The First Affiliated Hospital with Nanjing Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

FT819 in Subjects With B-cell Malignancies is being studied. Conditions: Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia • Eligibility: Key Inclusion Criteria: Diagnosis of B-cell lymphoma, CLL or B-ALL as described below: B-Cell Lymphoma: * Histologically documented lymphomas expected to express CD19 * Relapsed/refractory disease following at…. Goal: This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Fate Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether adding two cycles of blinatumomab to standard chemotherapy improves disease-free survival in newly diagnosed B-ALL or B-lymphoblastic lymphoma, including people with Down syndrome. - It is for children and young people with these diseases, with age ranges defined by diagnosis (roughly up to age 10 for non-DS B-ALL and up to 31 years for DS B-ALL and B-LLy). - The trial aims to find out if blinatumomab plus chemotherapy works better than chemotherapy alone at preventing the cancer from returning, and to learn about long-term outcomes and safety, plus some exploratory immune and genetic factors. - Key exclusions include prior cytotoxic chemotherapy for the current cancer (with certain exceptions), certain CNS disease statuses, active testicular leukemia in non-DS patients, and pregnancy. - Sponsor: National Cancer Institute. Status: ACTIVE_NOT_RECRUITING.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia is being studied. Conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia +1 • Eligibility: Inclusion Criteria: 1. Participants with a diagnosis of histologically confirmed relapsed or refractory (R/R) acute myeloid leukemia or R/R acute lymphoblastic leukemia for which no available standard therapies…. Goal: This phase I trial studies the side effects and best dose of palbociclib when given alone and in combination with sorafenib, decitabine, or dexamethasone in treating patients with leukemia that has come back (recurrent) or that does not respond to previous treatment (refractory). Palbociclib, sorafenib, and decitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests whether itacitinib, an immune-suppressing anti-inflammatory drug, given around a non‑myeloablative haploidentical peripheral blood stem cell transplant with high-dose posttransplant cyclophosphamide, can help older patients. - Researchers want to know if itacitinib can prevent severe cytokine release syndrome after transplant, reduce graft-versus-host disease, and possibly shorten the time patients need other immune-suppressing drugs. - Participants are people aged 60 and older with certain blood cancers who have a related, partially matched donor. - Key exclusions include active CNS leukemia, HIV, active HBV or HCV requiring treatment, pregnancy, and prior/allogeneic transplant or uncontrolled infection.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members is being studied. Conditions: Body Mass Index 25 or Greater, BRCA1 Gene Mutation, BRCA2 Gene Mutation +8 • Eligibility: Inclusion Criteria: * PILOTS I, II AND III: Body mass index (BMI) of 25 or higher OR \< 150 minutes of moderate to vigorous exercise per week OR…. Goal: This pilot clinical trial studies different types of energy balance interventions to see how well they work in increasing the physical activity levels of breast cancer gene-positive patients, Lynch syndrome-positive patients, chronic lymphocytic leukemia (CLL) survivors or family members of cancer survivors who are at high risk for cancer. Increasing exercise and eating healthy foods may help reduce the risk of cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a phase 1, open-label study testing an oral drug called LY3410738, which targets IDH1 and IDH2 mutations in adults with advanced blood cancers. - The study has two parts: dose escalation to find the maximum tolerated dose, followed by dose expansion to further assess safety and signs of activity in five cohorts. - Eligible participants include people with IDH-mutant advanced hematologic malignancies who have received prior therapy; in some arms, older AML patients or relapsed/refractory AML patients (US only) may enroll. - Key exclusions include active infection or active CNS disease, recent stem cell transplant or CAR-T therapy, pregnancy, and certain drug interactions or other serious conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia is being studied. Conditions: T-ALL • Eligibility: Inclusion Criteria: 1. Age ≥2 and ≤18 years old, male or female; 2. Subjects who have relapse or refractory T-cell lymphoblastic leukemia (T-ALL) according to the standards of…. Goal: To learn if the VGO-Cs01p can help to control CD7-positive relapsed/refractory acute T-lymphoblastic leukemia (R/R T-ALL) in children. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Jiao Tong University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL is being studied. Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma • Eligibility: Key Inclusion Criteria: * Unsuitable for chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) * Confirmed diagnosis of CD20-positive CLL or SLL, requiring treatment * Measurable disease by imaging…. Goal: To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; BeiGene.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma is being studied. Conditions: Lymphoma, Adult T-Cell Leukemia/Lymphoma, Lymphatic Diseases • Eligibility: Inclusion Criteria: Subjects must meet all of the following inclusion criteria to participate in this study: 1. Informed consent and HIPAA authorization for release of personal health information…. Goal: Adult T-cell leukemia/lymphoma (ATLL) is a rare form of cancer found mostly among people from the Caribbean islands, Western Africa, Brazil, Iran, and Japan. Most cases of this disease in the United States occur along the East Coast due to emigration from the Caribbean islands. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; UNC Lineberger Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) is being studied. Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma • Eligibility: Inclusion Criteria: 1. Be willing and able to provide written informed consent/assent for the trial. 2. Be ³ 18 years of age on day of signing informed consent.c…. Goal: The purpose of this study is to determine the most appropriate dose for the combination of ibrutinib and pembrolizumab and to see if the combination is active for the disease. The study will monitor for any side effects and if the combination of ibrutinib and pembrolizumab works in the cancers being studied. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Joshua Brody.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant is being studied. Conditions: Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS) +3 • Eligibility: Inclusion Criteria: General Eligibility (All Patients) * Must be \< 22 years of age * Diagnosed with a malignant disease * Must be fully informed about their illness…. Goal: The purpose of this study is to learn more about the effects of (classification determinant) CD34+ stem cell selection on graft versus host disease (GVHD) in children, adolescents, and young adults. CD34+ stem cells are the cells that make all the types of blood cells in the body. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Diane George.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies is being studied. Conditions: B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent • Eligibility: Inclusion Criteria: * Participants must be greater than or equal to 18 years of age. * Participants must have Eastern cooperative oncology group (ECOG) performance status of 0…. Goal: In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce these CAR+ T-cells and determine how well they work in the clinical setting. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Loyola University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. is being studied. Conditions: Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma +6 • Eligibility: 1. males and females aged 18-65 years; 2. Diagnosis and management at CLB for one of the following cancers: Hodgkin's lymphoma, aggressive non-Hodgkin's lymphoma, acute myeloid leukemia and…. Goal: INTRODUCTION: Approximately 44% of cancer survivors experience a deteriorated quality of life 5 years after diagnosis due to late onset of complications related to cancer treatments. The objective of the study is to evaluate the incidence rates of treatment-related complications, identify sub-clinical abnormalities and risk factors in patients participating in the PASCA post-treatment program. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Centre Leon Berard.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a prospective, multi-center trial testing a combination of decitabine (DEC) and venetoclax (VEN) for AML that developed from myeloproliferative neoplasms in patients who are unfit for intensive chemotherapy. - The goal is to learn whether VEN plus DEC can improve survival outcomes in these patients. - Eligible participants are adults with newly diagnosed, untreated sAML due to MPNs who are considered unfit for intensive treatment, have ECOG 0-2 (or reversible ECOG 3 with supportive care), can consent, and, for men with partners, will use barrier contraception. - Key exclusions include de novo AML, serious organ dysfunction (heart, liver, kidney), HIV, uncontrolled infections, QTc prolongation, and a history of cancer not in remission with limited life expectancy. - The trial is currently active but not recruiting, sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial is being studied. Conditions: Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma +3 • Eligibility: Inclusion Criteria: * Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug. * Male subject…. Goal: The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tissue Microarray of Hematological Malignancies is being studied. Conditions: Hematological Malignancies • Eligibility: Inclusion Criteria: * hematological malignancy/neoplasm Exclusion Criteria: * Non-sufficient data available. Goal: The aim of the study is to create new tools for improving management of patients with hematological malignancies by combining extensive clinical data from patients newly diagnosed with hematological malignancies and innovative laboratory analyses made on available tissue samples in regional biobanks from these patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Tampere University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) is being studied. Conditions: Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma • Eligibility: Inclusion Criteria: For subjects with LBCL: * Histologically confirmed diagnosis of relapsed/refractory large B-cell lymphoma at last relapse per WHO 2017 * At least 1 measurable lesion at…. Goal: This is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed or refractory large B-cell lymphoma and assess the safety of ALLO-501A in adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Allogene Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9 is being studied. Conditions: Acute Myeloid Leukemia, Melanoma, Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Diagnosis of acute myeloid leukemia (AML) and fit for allogeneic hematopoietic stem cell transplantation (alloHSCT), as assessed in the standard operating procedures. * Diagnosis of…. Goal: This is a scientific study to determine expression of vascular adhesion protein 1 (VAP-1) in cancer patients by 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT) before and after cancer treatment. Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; Turku University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study is testing adding Ivosidenib for IDH1 mutations or Enasidenib for IDH2 mutations to standard chemotherapy in adults with newly diagnosed AML or MDS-EB2 who are candidates for intensive chemotherapy. It uses induction therapy, followed by consolidation therapy and then maintenance therapy, to see if the combination can control the disease more effectively and for a longer time. The trial is currently active but not recruiting. Key exclusions include prior chemotherapy for AML/MDS-EB2 (except certain agents), having both IDH1 and IDH2 mutations, APL, active infection, significant heart disease, and pregnancy or contraception requirements for participants.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia is being studied. Conditions: Acute,Leukemia, Lymphoid • Eligibility: Inclusion Criteria: 1. Patients aged 18 to 60 years with De novo Philadelphia chromosome positive (Philadelphia chromosome positive or BCR/ABL transcript positive) acute lymphoblastic leukemia. 2. Eastern Cooperative…. Goal: In this single-center, open-label, no control,prospective clinical trial, a total of 30 Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients will be enrolled. Dasatinib 100 mg per day will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Institute of Hematology & Blood Diseases Hospital, China.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Reduce Sedentary Time in Acute Lymphoblastic Leukemia is being studied. Conditions: Acute Lymphoblastic Leukemia (ALL) • Eligibility: Inclusion Criteria: * 12-21 years of age at time of enrollment * Diagnosis of lymphoblastic leukemia/lymphoma treated with Children's Oncology Group (COG)-based maintenance chemotherapy \[B-cell acute lymphoblastic leukemia/lymphoma…. Goal: The goal of this feasibility trial is to test if a mobile health intervention, including a wearable fitness tracker with inactivity-triggered reminders to move, individualized coaching sessions, and an app-based peer support group, can decrease sedentary time (time spent sitting/lying down and inactive) in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) receiving maintenance chemotherapy. The main questions it aims to answer are: * Is the intervention a feasible and acceptable way to decrease sedentary time among adolescents and young adults (AYAs) with ALL? Phase/Status/Sponsor: Unknown phase; COMPLETED; Children's Hospital Los Angeles.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies is being studied. Conditions: Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL) +9 • Eligibility: Inclusion Criteria: * Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures * Histologically or cytologically confirmed diagnosis…. Goal: This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527 as a monotherapy and in combination with zanubrutinib or venetoclax. Phase/Status/Sponsor: Unknown phase; COMPLETED; Prelude Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Changing Over Time of Ascorbic Acid After Chemotherapy is being studied. Conditions: Leukemia (Both ALL and AML), Cancer of Lung, Myeloma • Eligibility: Inclusion Criteria: * 18 years or older * written informed consent * Require chemotherapy and will start this treatment in less than 1 month after registration for any…. Goal: Rationale: Recent studies showed that ascorbic acid (AA) stimulates proliferation and maturation of T lymphocytes and NK cells. Chemotherapy results in depletion of those cells and thereby an increased infection rate. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Maastricht University Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET) is being studied. Conditions: Advanced / Metastic Solid Tumors, Glioblastoma, Chronic Leukemia Lymphocytic • Eligibility: Inclusion Criteria: I1. Adult male or female patient with confirmed diagnosis of advanced/metastatic cancer to be treated with standard anti-cancer treatment according to : * For metastatic Small…. Goal: The proposal is to conduct a prospective, multi-cohort study aiming to decipher molecular profiles/biological characteristics of advanced cancer patients during the course of their disease with longitudinal and sequential analyses of tumor and liquid biopsies. This approach will allow i) to develop a model in order to predict tumor response / resistance in real life conditions and to better understand adaptive mechanisms and ii) to potentially propose therapeutic options to enrolled patients following the review of the biological/molecular data generated during this study and during a Molecular Tumor Board in case of disease progression. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Centre Leon Berard.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TKI Discontinuation in CML Patients of China is being studied. Conditions: Leukemia, Myelogenous, Chronic +2 • Eligibility: Inclusion Criteria: * Adults with CML-CP/AP and willingness of TKI discontinuation; * With ≥ 5 years frontline imatinib, reached MMR (major molecular response) in 2 years, with ≥…. Goal: The primary objective of this study is to describe the maintenance of the molecular remission after tyrosine kinase inhibitor (TKI) disconnection in chronic myeloid leukaemia (CML) patients in China in the real-world clinical practice setting. This is a post-marketing, non-interventional, single-arm, prospective registry study in adult patients with chronic phase (CP) and accelerated phase (AP) in China. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Shenzhen Second People's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years is being studied. Conditions: Acute Lymphoblastic Leukemia • Eligibility: Inclusion Criteria: Adults over 55 years diagnosed with acute lymphoblastic leukemia Ph 'negative and not previously treated with frailty (\> 3 points in the Charlson comorbidity index) Exclusion…. Goal: The biological characteristics of the adult LAL, karyotypic and phenotypic particular, are fundamentally different from those of Acute Lymphoblastic Leukemia (ALL) children and, consequently, the results of treatment are substantially lower. Additionally, elderly patients tolerate the drugs considered relatively low-key in the management of the LAL and suffer more toxicity. Phase/Status/Sponsor: Unknown phase; UNKNOWN; PETHEMA Foundation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL is being studied. Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma • Eligibility: Inclusion Criteria: Subjects who meet each of the following inclusion criteria are eligible to participate in this study: 1. Age ≥18 years old. 2. Pathologically confirmed CLL/SLL according…. Goal: The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Ascentage Pharma Group Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies is being studied. Conditions: T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma • Eligibility: Inclusion Criteria: 1. Aged from 14 to 70 years; 2. Expected survival over 60 days; 3. Eastern Cooperative Oncology Group score 0-2; 4. Diagnosed as T-cell hematologic malignancies…. Goal: This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of anti-CD7 chimeric antigen receptor(CAR)-modified T cells(CAR7-Ts) in patients with relapsed or refractory T lymphoid malignancies. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL is being studied. Conditions: Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma • Eligibility: Inclusion Criteria: * Cohort 1: Confirmed diagnosis of TP53wt DLBCL (WHO); R/R DLBCL after at least 2 prior lines of treatment or 1 prior for patients who are…. Goal: This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy) Phase/Status/Sponsor: Unknown phase; UNKNOWN; Kartos Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia is being studied. Conditions: Acute Lymphoblastic Leukemia • Eligibility: Inclusion Criteria: * Diagnosed with ALL ≥5 years ago * \<18 years of age at time of ALL diagnosis Exclusion Criteria: * None. Goal: The goal of this observational study is to quantify the burden of particularly severe, long-term adverse effects in childhood acute lymphoblastic leukemia (ALL) survivors. The adverse effects include 21 severe health conditions recently selected and defined as Severe Toxicities by an international collaboration of ALL consortia. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Rigshospitalet, Denmark.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts is being studied. Conditions: B-Cell Acute Lymphoblastic Leukemia, Adult • Eligibility: Inclusion Criteria: * Relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL) having received at least 1 prior line of therapy * Philadelphia chromosome positive (Ph+), or Breakpoint Cluster…. Goal: This is a Phase I/II study of blinatumomab in combination with pembrolizumab in adult patients with relapsed or refractory B-lineage ALL (B-ALL). The primary objective of this study is to determine if the addition of pembrolizumab to blinatumomab improves the Complete Response Rate (CR) and Complete Remission with Partial Hematologic Recovery (CRh) relative to blinatumomab alone in adult subjects with relapsed or refractory B-cell acute lymphoblastic leukemia with high bone marrow lymphoblast percentage (\>50% lymphoblasts). Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, San Diego.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients is being studied. Conditions: Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma +14 • Eligibility: Inclusion Criteria: \- Exclusion Criteria: \-. Goal: AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Phase/Status/Sponsor: Unknown phase; AVAILABLE; AVM Biotechnology Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Financial Difficulty in Patients With Blood Cancer is being studied. Conditions: Chronic Lymphocytic Leukemia, Multiple Myeloma • Eligibility: Inclusion Criteria: PATIENT ELIGIBILITY CRITERIA * Patients must have current diagnosis of chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) * Patients' medical records must be available to…. Goal: This is a hypothesis-driven, observational, cross-sectional, multi-site study of the financial difficulties experienced by patients undergoing treatment for multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). It is composed of a patient survey (n=250) (Appendix A), a physician survey (n=100) (Appendix B), and a practice survey completed by each site enrolling patients onto this study (Appendix C). Phase/Status/Sponsor: Unknown phase; COMPLETED; UNC Lineberger Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

INCB018424 in Patients With Advanced Hematologic Malignancies is being studied. Conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome +1 • Eligibility: Inclusion Criteria: 1. Must be at least 18 years of age. 2. Patients must have relapsed/refractory leukemias for which no standard therapies exist. Patients with poor-risk myelodysplasia (MDS)…. Goal: The goal of this clinical research study is to learn if ruxolitinib can help to control advanced hematological malignancies. The safety of this drug will also be studied. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy is being studied. Conditions: Lymphoid Malignancies (New or Relapsed), Acute Lymphoblastic Leukemia, Burkitt Lymphoma +3 • Eligibility: Inclusion Criteria: 1. Patients must have a diagnosis of one of the following lymphoid malignancies (new or relapsed): * Acute Lymphoblastic Leukemia (B and T cell, Philadelphia Chromosome…. Goal: This is a pilot study, assessing the feasibility, safety and toxicity of an mTOR (mammalian target of Rapamycin) inhibitor (MTI), rapamycin, when administered with HyperCVAD (Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicine and Dexamethasone), with an ultimate goal to perform a phase II study to evaluate response rates and survival in adults with Acute Lymphoblastic Leukemia (ALL) and aggressive lymphoid malignancies. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sidney Kimmel Cancer Center at Thomas Jefferson University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies is being studied. Conditions: Hematological Malignancies, Leukemia, Lymphoma +2 • Eligibility: Inclusion Criteria: 1. Any patient with a hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been…. Goal: This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sidney Kimmel Cancer Center at Thomas Jefferson University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies is being studied. Conditions: Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute +2 • Eligibility: Inclusion Criteria: * Malignant Disease * Chronic myleogenous leukemia in chronic or accelerated phase * Acute lymphoblastic leukemia (ALL) * First remission high-risk ALL (Ph+, t( 4-11) infants).…. Goal: The purpose of this study is to show that myeloablative hematopoietic progenitor cell transplantation (HPCT) continues to offer acceptable disease-free survival for select patients requiring HPCT. Phase/Status/Sponsor: Unknown phase; COMPLETED; Ann & Robert H Lurie Children's Hospital of Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL) is being studied. Conditions: Lymphoma • Eligibility: DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed advanced aggressive non-Hodgkin's lymphoma (NHL), including any of the following subtypes: * B-cell NHL, including any of the following subtypes: *…. Goal: RATIONALE: BI 2536 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of BI 2536 in treating patients with refractory or relapsed advanced non-Hodgkin's lymphoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Boehringer Ingelheim.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma is being studied. Conditions: Multiple Myeloma • Eligibility: Accepts Healthy Volunteers: No Inclusion Criteria: 1. Subjects with a confirmed diagnosis of Multiple Myeloma who have had one and no more than three prior regimens for MM…. Goal: The purpose of this study is to assess the safety and benefits of the investigational study drug, KW-2478, when given with bortezomib (Velcade®), a drug approved for the treatment of Multiple Myeloma (MM). The primary objectives: * To establish the safety, tolerability, and recommended Phase II dose (RP2D) of KW-2478 in combination with bortezomib (Phase I); * To assess the overall response rate (ORR) when subjects with advanced MM are treated (Phase II). Phase/Status/Sponsor: Unknown phase; COMPLETED; Kyowa Kirin Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving is being studied. Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome +1 • Eligibility: Inclusion Criteria: 1. Male and female patients aged ≥ 18 years. 2. Patients with relapsed /refractory AML, ALL, or MLL with rearrangement of the MLL gene, including 11q23…. Goal: The purpose of this study is to determine the safe dose of EPZ-5676, to evaluate the safety of EPZ-5676 in patients with advanced hematologic malignancies, and to conduct a preliminary assessment of the anti-leukemia activity of EPZ-5676 in patients with acute leukemias bearing rearrangements of the MLL gene. Currently this study is in the MLL-r restricted/expansion phase and is only enrolling patients with rearrangements involving the MLL gene, including 11q23 or partial tandem duplications (PTD). Phase/Status/Sponsor: Unknown phase; COMPLETED; Epizyme, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia is being studied. Conditions: Acute Myeloid Leukemia • Eligibility: Inclusion Criteria: * The following patients with acute myeloid leukemia (AML) are eligible: * De novo AML M4 or M5 FAB subtype or high eIF4E. * Secondary AML…. Goal: The purpose of the study is to determine the maximum tolerated dose of ribavirin, when given in combination with low-dose ara-C and to determine if it is safe and well-tolerated in patients with acute myeloid leukemia. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jewish General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers is being studied. Conditions: Glioblastomas, Sarcoma, Astrocytoma +2 • Eligibility: * INCLUSION CRITERIA FOR CHILDREN: * Patients diagnosed with a high-risk/high-grade cancer (e.g., high-grade brain tumors, relapsed/refractory acute lymphoblastic leukemia, acute myeloid leukemia, high-grade sarcoma) characterized by poor…. Goal: Background: People cope with cancer in different ways. Mindfulness means focusing on the present moment with an open mind. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology is being studied. Conditions: Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Childhood Acute Myeloid Leukemia +5 • Eligibility: Inclusion Criteria: * Site willingness to participate in all 3 aims * AIM 1 - ELIGIBILITY CRITERIA FOR INCLUSION IN RETROSPECTIVE CENTRALIZED CHART REVIEW * Received care as…. Goal: This research trial studies the use of clinical practice guidelines by pediatric oncology healthcare providers in order to identify, understand, and overcome barriers to them. The treatments for childhood cancers are intense and result in a high rate of symptoms which require support by healthcare providers. Phase/Status/Sponsor: Unknown phase; COMPLETED; Children's Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia is being studied. Conditions: Leukemia • Eligibility: Cohort 1 (Initial cohort: Relapsed AML with previous remission \>/= 3 months) is permanently closed to accrual DISEASE CHARACTERISTICS * Patients must have a previous morphologically confirmed diagnosis…. Goal: RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Pravastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; SWOG Cancer Research Network.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) is being studied. Conditions: Acute Lymphoblastic Leukemia, Complete Hematologic Remission (CHR), Persistent/Recurrent Minimal Residual Disease (MRD) • Eligibility: Inclusion Criteria: * Adult subjects with Ph+ ALL in CHR (1st or 2nd) with MRD positivity confirmed at baseline, older or equal to 60 years or not eligible…. Goal: The present study aims at studying how safe and tolerable a new therapy for patients with Acute Lymphoblastic Leukemia (ALL) is. This new therapy consists of an immunotherapy, that is an approach focusing on the immune system, and it targets ALL patients in complete remission but who may still have the disease at a cellular level (this is called 'minimal residual disease'). Phase/Status/Sponsor: Unknown phase; COMPLETED; Gruppo Italiano Malattie EMatologiche dell'Adulto.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib is being studied. Conditions: Acute Myeloid Leukemia • Eligibility: Inclusion Criteria: * Patients with confirmed diagnosis of AML according to WHO-2016 \[27\] (except acute promyelocytic leukemia) either de novo AML, AML after preceding myelodysplastic or myeloproliferative syndrome…. Goal: The long-term outcome of patients with acute myeloid leukemia (AML) remains poor, with less than 30% of patients achieving long lasting remission or cure. This poor outcome is largely due to refractoriness to induction chemotherapy as well as relapses during and after completion of intensive induction and consolidation therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital Heidelberg.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma is being studied. Conditions: Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma • Eligibility: INCLUSION CRITERIA: * Must have relapsed or refractory precursor B-cell acute lymphoblastic leukemia or acute lymphoblastic lymphoma. * Participants with leukemia must meet one of the following: 1.…. Goal: The overall objective of this protocol is to improve the cure rate of relapsed precursor B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma. This phase II trial is studying risk-directed therapy for B-lymphoblastic leukemia or lymphoma in first relapse. Phase/Status/Sponsor: Unknown phase; COMPLETED; St. Jude Children's Research Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment is being studied. Conditions: Leukemia, Lymphoma, Small Intestine Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed T-cell or natural killer (NK)-cell lymphoma, including any of the following subtypes: * Blastic NK-cell lymphoma * T/NK-cell lymphoma/leukemia * Adult T-cell lymphoma/leukemia…. Goal: RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine and to see how well it works in treating patients with T-cell or natural killer-cell lymphoma that has relapsed or not responded to previous treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia is being studied. Conditions: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia • Eligibility: Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent or have parental consent. * Age ≥ 18 years * Pathological confirmation by…. Goal: In this pilot study, eligible patients will be treated with 5 days of low dose daunorubicin for one cycle only. Any patient who receives treatment on this protocol will be evaluable for toxicity. Phase/Status/Sponsor: Unknown phase; COMPLETED; Tara Lin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax is being studied. Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma • Eligibility: Inclusion Criteria: * Diagnosis of CLL per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2018 criteria * Received venetoclax for at least 12 cycles, with MRD \> 0.01%…. Goal: To learn if the combination of LOXO-305 (pirtobrutinib) and venetoclax can help to control previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Phase/Status/Sponsor: Unknown phase; TERMINATED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.